3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
4
Lymphoid
3
Plasma cell
1
Myeloid
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Classical hematology
1
CNS
1
Breast
1
Conditions
Brain Neoplasms
4
Glioma
3
Thyroid Cancer, Papillary
2
Sarcoma
2
Salivary Gland Neoplasms
2
Neoplasm Metastasis
2
Melanoma
2
Central Nervous System Neoplasms
2
Wilms Tumor
1
Sarcoma, Ewing
1
Recurrence
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neuroendocrine Tumors
1
Neuroblastoma
1
Nephroma, Mesoblastic
1
Neoplasms by Site
1
Neoplasms by Histologic Type
1
Neoplasms
1
Medulloblastoma
1
Lymphoproliferative Disorders
1
Lymphoma, Large-Cell, Anaplastic
1
Hematologic Neoplasms
1
Head and Neck Neoplasms
1
Colorectal Neoplasms
1
Cholangiocarcinoma
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Interventions
trametinib
2
dabrafenib
2
Specimen Handling
2
Nivolumab
2
Magnetic Resonance Spectroscopy
2
ulixertinib
1
trastuzumab biosimilar HLX02
1
thymoglobulin
1
temsirolimus
1
sapanisertib
1
ropidoxuridine
1
romidepsin
1
relatlimab
1
pertuzumab
1
palbociclib
1
osimertinib
1
omipalisib
1
larotrectinib
1
ipatasertib
1
fludarabine
1
erdafitinib
1
entrectinib
1
defactinib
1
copanlisib
1
cobimetinib
1
ceritinib
1
cc-486
1
capmatinib
1
capivasertib
1
bintrafusp alfa protein, human
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Hematologic Neoplasms
×
entrectinib
×
CNS
×
Clear all
NCT05770544
2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
30 enrolled